Sevde Topuz

Dr. Sevde Topuz

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2026 in Cerrahpasa Medical Journal
Verified
Journal Article
Open access
PDF file
SÇSimay Çokgezer
Simay Çokgezer
SASelay Artan
Selay Artan
STSevde Topuz
Sevde Topuz
MŞMuhammet şenkal
Muhammet şenkal
AAAbdulmunir Azizy
Abdulmunir Azizy
SKSenem Karabulut
Senem Karabulut
Objective: This study aimed to evaluate the impact of anti-epidermal growth factor receptor (anti-EGFR)–based maintenance therapy administered after first-line chemotherapy combined with anti-EGFR treatment on progression-free survival (PFS) and overall survival (OS) in patients with RAS wild-type metastatic colorectal cancer (mCRC), using real-world data. Methods: Patients followed at a single center between 2015 and 2025 were retrospectively analyzed. A total of 37 RAS wild-type patients who achieved disease control after first-line chemotherapy combined with anti-EGFR therapy were included. Patients were divided into a maintenance therapy group (n = 19) and an active surveillance group (n = 18). Survival analyses were performed using the Kaplan–Meier method, groups were compared using the log-rank test, and a landmark approach was applied to minimize immortal time bias. Results: At a median follow-up of 27.4 months, median PFS was 11.4 months in the maintenance group and 5.4 months in the surveillance group, without reaching statistical significance (P = .133). In contrast, median OS was significantly longer in the maintenance group (56.9 months vs. 9.6 months; P = .041). Additionally, higher rates of transition to subsequent lines of therapy were observed in patients receiving maintenance therapy. Conclusion: Anti-EGFR–based maintenance therapy was associated with numerically prolonged PFS and improved treatment continuity in patients with RAS wild-type mCRC. Although a significant difference in OS was observed, this finding should be interpreted cautiously given the limited sample size, retrospective design, and potential influence of selection bias and subsequent therapies. Larger prospective studies are warranted to better define the role of anti-EGFR maintenance therapy in clinical practice. Cite this article as: Çokgezer S, Artan S, Topuz S, et al. Effect of maintenance anti-EGFR therapy on survival in RAS wild-type metastatic colorectal cancer: real-world data. Cerrahpaşa Med J 2026, 50, 0069, doi: 10.5152/cjm.2026.26069.

28 March 2026 in Medicina
Verified
Journal Article
Open access
PDF file
SÇSimay Çokgezer
Simay Çokgezer
ASAysel Seferaliyeva
Aysel Seferaliyeva
STSevde Topuz
Sevde Topuz
MŞMuhammet şenkal
Muhammet şenkal
NANaziye Ak
Naziye Ak
PSPınar Mualla Saip
Pınar Mualla Saip
Background and Objectives: Invasive lobular carcinoma (ILC) is a breast cancer subtype with a controversial surgical management due to its diffuse infiltrative growth pattern and increased tendency for multicentricity. This study aimed to compare the effects of breast-conserving surgery (BCS) and mastectomy on long-term overall survival (OS) and progression-free survival (PFS) in patients diagnosed with ILC. Materials and Methods: In this single-center, retrospective, observational study, 255 patients with histopathologically confirmed ILC between 2017 and 2025 were included. Patients who underwent surgical treatment were divided into two groups according to the surgical approach: BCS (n = 94) and mastectomy (n = 141). Survival analyses were performed using the Kaplan–Meier method, and comparisons between groups were assessed with the log-rank test. Factors affecting survival were evaluated using Cox regression analysis. Results: The median age of the patients was 53 years (range, 28–85), and the median follow-up duration was 31.8 months. Of the cases, 76.9% were classic-type ILC and 70.9% had stage I–II disease. The rate of negative surgical margins was 87.6%. No statistically significant differences were observed between the BCS and mastectomy groups in terms of estimated median PFS (87.4 months vs. 86.7 months; p > 0.05) or estimated median OS (87.7 months vs. 115.7 months; p > 0.05). Multivariable analyses demonstrated that the type of surgery was not an independent prognostic factor for survival. Conclusions: This study shows that, with appropriate patient selection and adequate surgical margin control, BCS provides oncologic survival outcomes comparable to mastectomy in ILC. The choice of surgical approach should be individualized based on tumor biology, stage, and multidisciplinary evaluation rather than histological subtype alone.

30 June 2026 in Cerrahpasa Medical Journal
Verified
Journal Article
Open access
SÇSimay Çokgezer
Simay Çokgezer
MŞMuhammet şenkal
Muhammet şenkal
ASAysel Seferaliyeva
Aysel Seferaliyeva
STSevde Topuz
Sevde Topuz
PSPınar Mualla Saip
Pınar Mualla Saip
NANaziye Ak
Naziye Ak
Objective: This study aimed to compare disease-free survival (DFS) and overall survival (OS) between patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative invasive lobular carcinoma (ILC) who received adjuvant chemotherapy plus endocrine therapy and those who received adjuvant endocrine therapy alone in a real-world setting. Methods: In this single-center retrospective cohort study, patients diagnosed with stage I-III HR-positive, HER2-negative ILC who underwent curative surgery between January 2017 and June 2025 were included. Patients with metastatic disease, prior neoadjuvant therapy, or incomplete follow-up were excluded. Patients were categorized according to receipt of adjuvant chemotherapy. All patients received standard adjuvant endocrine therapy. The primary endpoints were DFS and OS. Results: A total of 154 patients were included, with a median follow-up of 29.8 months. Patients who received adjuvant chemotherapy had higher-risk clinicopathological features, including more advanced tumor stage and nodal involvement. During follow-up, 6 recurrences (3.9%) were observed. Median DFS was 84.5 months in the endocrine therapy alone group and 95.5 months in the chemotherapy plus endocrine therapy group (log-rank P = .962). Median OS was not reached; the estimated mean OS was 96.4 months. Median OS was 85.6 months in the non-chemotherapy group and 95.8 months in the chemotherapy group (log-rank P = .785). In multivariable analysis, chemotherapy was not an independent predictor of DFS or OS. Conclusion: In this real-world cohort of HR-positive, HER2-negative ILC, no statistically significant difference in DFS or OS was observed between treatment groups. These findings should be interpreted with caution given the limited number of events and baseline risk imbalance. The potential survival benefit of chemotherapy in this subtype may be limited and should be considered in individualized treatment decisions. Cite this article as: Çokgezer S, Şenkal M, Safaraliyeva A, Topuz S, Saip PM, Ak N. Real-world survival outcomes of adjuvant chemotherapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative invasive lobular carcinoma. Cerrahpaşa Med J 2026, 50, 0038, doi: 10.5152/cjm.2026.26038.